LY2886721
Cat. No.：YN380075
CAS No. ：1262036-50-9
| 产品名称: | LY2886721 |
| CAS No.: | 1262036-50-9 |
| Chemical Name: | N-[3-[(4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide |
| Synonyms: | LY2886721;N-(3-((4AS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide;N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide;LY-28867 |
| 分子量: | 390.41 |
| 分子式: | C₁₈H₁₆F₂N₄O₂S |
| SMILES: | FC1=CN=C(C=C1)C(NC2=CC=C(C([C@@]34[C@]([H])(CSC(N)=N4)COC3)=C2)F)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | LY2886721 是一种有效的，选择性的，口服活性的 β 位淀粉样蛋白前体蛋白裂解酶 1 (BACE1) 抑制剂，对重组人BACE1的IC50为 20.3 nM。LY2886721 对BACE1的选择性高于对组织蛋白酶 D，胃蛋白酶和肾素的选择性，但缺乏对BACE2(IC50为 10.2 nM) 的选择性。LY2886721 可穿越血脑屏障，并可用于阿尔茨海默氏病的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
May, P.C., Boggs, L.N., Brier, R., et al.Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's diseaseJ. Alzheim. Assoc.8(4),95(2003)
Vassar, R., Kovacs, D.M., Yan, R., et al.The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potentialJ. Neurosci.29(41),12787-12794(2009)
